Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

CVRx Barostim illustration

CVRx, Abbott share long-term heart failure data at THT 2023

CVRx and Abbott used the second annual THT conference as an opportunity to present updated data on their signature heart failure solutions.

March 22, 2023
FDA Recall

FDA announces new Class I recall of troubled heart devices

The recall includes approximately 2,300 devices distributed to customers prior to July 24, 2017. There have been 44 complaints about this issue so far.

March 17, 2023
Money dollar investments

Startup focused on heart failure monitoring raises $25M with help from Novo Holdings, Medtronic

The round was led by two new investors, Novo Holdings and Andera Partners. Several existing investors, including Medtronic, also participated.

March 17, 2023
New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease. #ACC23

Long-term fasting improves heart-related outcomes for at-risk COVID-19 patients

New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.

March 13, 2023
ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

March 10, 2023
Hospital Costs

High costs limit the value of dapagliflozin, empagliflozin as heart failure treatments

SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

March 8, 2023
Atul Verma, MD, head of cardiology at McGill University Health Centre

Day 3 at ACC.23 features late-breaking studies on pulsed-field ablation, other new technologies

The third and final day of ACC.23 featured a key update on Medtronic's pulsed-field ablation technology and many other late-breaking clinical studies. 

March 6, 2023
ACC 2023 ACC.23 American College of Cardiology

Day 2 at ACC.23 features late-breaking studies on TEER, TAVR, EHR alerts and much more

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

March 5, 2023

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup